369 related articles for article (PubMed ID: 14984376)
1. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
[TBL] [Abstract][Full Text] [Related]
2. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
3. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
4. Management of fistulas in patients with Crohn's disease: antibiotic to antibody.
Paré P
Can J Gastroenterol; 2001 Nov; 15(11):751-6. PubMed ID: 11727005
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
6. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study.
Roumeguère P; Bouchard D; Pigot F; Castinel A; Juguet F; Gaye D; Capdepont M; Zerbib F; Laharie D
Inflamm Bowel Dis; 2011 Jan; 17(1):69-76. PubMed ID: 20623697
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
11. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
12. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.
Tougeron D; Savoye G; Savoye-Collet C; Koning E; Michot F; Lerebours E
Dig Dis Sci; 2009 Aug; 54(8):1746-52. PubMed ID: 19003531
[TBL] [Abstract][Full Text] [Related]
13. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
14. Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
16. Fistula response to methotrexate in Crohn's disease: a case series.
Mahadevan U; Marion JF; Present DH
Aliment Pharmacol Ther; 2003 Nov; 18(10):1003-8. PubMed ID: 14616166
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
[TBL] [Abstract][Full Text] [Related]
18. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
20. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
